Engflag

Claribid

Quick links to important sections

Claribid

Claribid_CS

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Claribid

Quick Facts: Claribid

Property Description
Active ingredient Clarithromycin
Manufacturer Abbott Healthcare (Implied focus: India)
Pharmacological class Macrolide antibiotic, Anti-infective agent
General purpose Counters bacterial growth associated with infection
Origin/Type Semi-synthetic prescription drug (Rx-only)

The Core Identity and Classification

Claribid is the trade name for the active drug Clarithromycin, which is a semi-synthetic macrolide antibiotic and an anti-infective agent. It is manufactured by Abbott Healthcare and generally functions as a prescription-only medication to address illnesses resulting from bacterial proliferation. Clarithromycin is chemically derived from the older macrolide erythromycin, but its structure has been modified. This improved structural profile allows the drug to reliably reach effective concentrations necessary to manage a range of bacterial infections, including those affecting the respiratory system and skin. The drug is frequently utilized in therapy regimens where penicillin allergy or resistance is a primary consideration.

Composition and Functional Principle

Clarithromycin, the single-ingredient product in Claribid, is formulated in multiple pharmaceutical preparations, including standard tablets, specialized extended-release tablets, granules used to prepare an oral suspension (liquid form), and a sterile solution for intravenous injection. The availability of both tablets and a suspension makes Claribid suitable for broad patient demographics.

The functional principle relies on the drug's ability to interfere with the processes bacteria use to create the essential proteins needed for their survival and replication. This action primarily results in a bacteriostatic effect, meaning it prevents the bacterial population from growing and spreading. Macrolides achieve high tissue concentrations, meaning the drug readily distributes to the relevant areas of infection. This effective tissue penetration is fundamental to its role in successfully managing the infection.

What side effects are possible with Claribid?

Possible Side Effects and Safety Information

Claribid (clarithromycin) is associated with a range of adverse reactions, with gastrointestinal disturbances being the most frequently reported in clinical trials. These common effects (occurring in ge 1% to <10% of patients) include abdominal pain, diarrhea, nausea, vomiting, and dysgeusia (altered taste sensation).

Serious and Clinically Significant Adverse Reactions

Regulatory documents emphasize several serious risks, typically classified as uncommon or rare events:

  • Cardiovascular Risk: Claribid can cause QT interval prolongation and ventricular arrhythmias, including torsade de pointes, which may be fatal. Caution is required in patients with pre-existing heart conditions or uncorrected electrolyte disturbances.
  • Hepatotoxicity: Cases of severe hepatic dysfunction (hepatitis, cholestasis), with or without jaundice, have been reported, occasionally leading to fatal hepatic failure. Discontinuation is recommended if signs of liver injury occur.
  • Severe Hypersensitivity: Life-threatening immune reactions, such as Anaphylaxis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms), have been documented.
  • Antibiotic-Associated Diarrhea: This includes Clostridioides difficile-associated diarrhea (CDAD), which can range from mild diarrhea to fatal colitis.

Restrictions and Population-Specific Safety

The use of Claribid is contraindicated with several medications due to the potential for serious drug interactions, including certain statins (lovastatin, simvastatin), ergot alkaloids, and drugs that significantly prolong the QT interval (e.g., pimozide, cisapride). Use during pregnancy is not generally recommended unless no alternative therapy is appropriate, due to animal findings suggesting potential harm to the fetus. Caution is advised for patients with renal or hepatic impairment, as dose adjustment may be necessary in severe cases.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Claribid (clarithromycin) is primarily associated with symptoms affecting the gastrointestinal system.

Documented Overdose Presentations and Manifestations

Symptoms reported in cases of overdose typically include:

  • Stomach pain (abdominal pain)
  • Nausea
  • Vomiting
  • Diarrhea

These symptoms may be a sign of increased drug exposure and can potentially worsen the patient's condition, especially in children, where immediate consultation with a doctor is advised.

Required Emergency Actions

Urgent medical attention is required if an overdose is suspected. Procedural instructions for an overdose situation direct users to contact professional help based on the severity of the victim's state:

  • For immediate guidance on poison control: Call the poison control helpline at 1-800-222-1222.
  • For life-threatening emergencies: Immediately call emergency services at 911 if the victim has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Regulatory information emphasizes that patients, or those caring for them, should seek emergency help for any severe change in status resulting from overexposure to the medication.

Therapeutic Uses of Claribid

What Claribid Treats: Main Uses and Benefits

Claribid is generally used to help manage bacterial infections across several key domains. It is applied across therapeutic domains involving heightened symptomatic activity, such as acute community-acquired pneumonia, sinusitis, and tonsillitis, as well as localized infections like acute otitis media (ear infection), cellulitis, and impetigo. Furthermore, it is a key component in specialized combination therapies aimed at addressing the bacterium H. pylori and serves as an important alternative treatment for patients with penicillin allergies.

In these contexts, the medication is commonly used to help with the associated infection, which contributes to easing the symptom burden of fever, pain, and inflammation. It is relevant when supportive symptom management is appropriate and assists with maintaining functional stability during management of both acute and challenging chronic infections.

Quick Fact: Relief for Key Symptom Clusters

Symptom Cluster Conditions Relevant General Benefit Provided
Respiratory Distress Pneumonia, Acute Bronchitis May assist with easing cough and chest congestion burden.
Localized Pain/Swelling Otitis Media, Cellulitis May contribute to easing pain and inflammation.
Systemic Discomfort Pharyngitis, Systemic MAC May help ease fever and overall malaise.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Claribid?

The population eligibility for Claribid (Clarithromycin) is strictly defined by regulatory documents, outlining groups who must not use the medicine (contraindications) and those for whom use is restricted.

Absolute Contraindications

Clarithromycin is contraindicated and must not be used by individuals with:

  • A known allergy or hypersensitivity to clarithromycin, erythromycin, or any other macrolide antibiotic.
  • A history of cholestatic jaundice or hepatic dysfunction associated with prior use of the medicine.
  • Pre-existing QT prolongation, certain ventricular cardiac arrhythmias (including Torsades de pointes), or uncorrected low potassium (hypokalaemia).
  • Severe hepatic failure in combination with severe renal impairment.

Age and Organ Function Restrictions

Population Group Eligibility Status
Infants (< 6 months) Use is not established for general bacterial infections.
Children (< 12 years) Tablet formulations are not recommended; oral suspension is typically used.
Pregnancy/Lactation Use is not recommended; safety is not established, and caution is advised.
Severe Renal Impairment Use is restricted, requiring official adjustment due to limited clearance.

These guidelines define the specific population authorized to use Clarithromycin under standard labeled conditions.

What should I know about interactions with other medicines?

Claribid (clarithromycin) is a potent inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme, which is responsible for metabolizing many other medications in the body. This inhibition can lead to significantly increased blood levels of co-administered drugs, raising the risk of serious or life-threatening adverse effects. Therefore, it is crucial to inform your doctor about all prescription, over-the-counter medicines, and herbal supplements you are taking.

Key contraindicated and highly cautioned interactions include:

Interacting Medicine Class/Type Potential Risk/Effect Clinical Guidance
Colchicine (for gout) Greatly increased toxicity, which can be fatal, especially in patients with kidney or liver impairment. Concomitant use is contraindicated.
Statins (e.g., simvastatin, lovastatin) Increased risk of severe muscle toxicity, including rhabdomyolysis. Simvastatin and lovastatin are contraindicated. Other statins may require temporary discontinuation or dose adjustment.
Ergot Alkaloids (e.g., ergotamine, dihydroergotamine for migraines) Increased risk of severe peripheral vasoconstriction (narrowing of blood vessels) and reduced blood flow. Concomitant use is contraindicated.
Antiarrhythmics (e.g., quinidine, disopyramide) Increased risk of serious, prolonged heart rhythm abnormalities (QT prolongation). Requires close monitoring of heart rhythm and drug blood levels.
Oral Anticoagulants (e.g., warfarin) Increased risk of bleeding. Requires frequent monitoring of the International Normalized Ratio (INR).

Medications that induce CYP3A4 activity, such as rifampicin, phenytoin, and carbamazepine, can decrease Claribid's effectiveness by lowering its blood concentration. Your healthcare provider must be aware of all concurrent medications to manage these potential interactions safely.

Mechanism of Action

Molecular Targeting of Bacterial Protein Synthesis

Claribid (Clarithromycin) exerts its primary effect by reversibly binding to the 50S ribosomal subunit of susceptible bacteria, specifically targeting the 23S ribosomal RNA (rRNA). This interaction blocks the exit tunnel for newly forming proteins, acting as an inhibitor to halt the critical process of polypeptide chain elongation. The physiological consequence is a rapid bacteriostatic effect, suppressing microbial growth and enabling host defense mechanisms to eliminate the non-reproducing pathogen population.

Dual Active Component and Mechanistic Constraints

Clarithromycin works synergistically with its major metabolite, 14-OH Clarithromycin, which shares the same ribosomal inhibitory mechanism, thereby resulting in a complementary total antimicrobial effect. However, this mechanism is functionally constrained by bacterial defense systems, such as efflux pumps that actively expel the drug, and target-site modifications in the 23S rRNA, both of which reduce or neutralize the drug's ability to engage its molecular target. This means the necessary state of bacterial growth arrest cannot be achieved, and the ribosomal target remains functionally uninhibited.

Dosage and Administration Information

How to Use Claribid

The usage of Claribid, which contains the active ingredient clarithromycin, is strictly defined by the dosage form and the patient’s clinical status. Clarithromycin is administered through two primary routes: oral (using tablets or suspension) and intravenous (IV) infusion.

Official Dosing and Frequency

The standard adult dosing regimen is typically 250 mg twice daily for the immediate-release (IR) oral forms or 1000 mg once daily for the extended-release (ER) tablets. Intravenous administration is generally fixed at 500 mg twice daily for acute therapy, intended as a short-term measure (usually 2 to 5 days) before transitioning the patient to the oral form.

Administration Guidelines

Intake requirements vary based on formulation:

  • IR Tablets and Suspension: These can be taken with or without food.
  • ER Tablets: These must be taken with food to ensure appropriate absorption and must be swallowed whole, without being chewed or crushed.

Population-Specific Adjustments

Dose modification is applied for specific populations. For patients with severe kidney impairment (creatinine clearance less than 30 mL/min), the dosage is typically reduced by half (50%). In pediatric patients, the oral suspension is dosed based on body weight, commonly 15 mg/kg/day divided every 12 hours. Treatment for most acute infections typically lasts 6 to 14 days, and the entire prescribed course must be completed.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Early-Stage Parkinson's Disease (PD)

Research investigated the scope and focus of studies conducted on this combination in Parkinson's disease (PD) and its role as an initial therapy was examined in certain research. The combination of levodopa and carbidopa is a long-established foundational treatment in managing PD.

The studies examined whether the drug could influence 'off' time—periods when motor symptoms return—and daily function. Studies assessed changes in motor symptom severity over time and compared the observations to other management options investigated for early-stage PD, focusing on outcomes measured using standardized scales.

Managing Motor Fluctuations and Dyskinesia

Studies investigated the effects of long-term use, particularly in patients with advanced disease who experience motor complications. The research compared the observed frequency and duration of involuntary movements, known as dyskinesia, to findings reported for levodopa treatment alone.

Outcome Studied Focus of Research Key Measurement Used
Motor Function Changes in rigidity, tremor, and bradykinesia Unified Parkinson's Disease Rating Scale (UPDRS)
Dyskinesia Reduction in duration and severity of involuntary movements Unified Dyskinesia Rating Scale (UDysRS)
Quality of Life (QoL) Impact on daily living and overall well-being Parkinson's Disease Questionnaire (PDQ-8)

Other research explored the impact of the combination on quality of life, particularly for participants included in studies focused on advanced stages of the disease where symptom control can be more challenging. Results consistently indicate that optimizing dopaminergic therapy is associated with improvements across various motor and non-motor domains.

Key Studies & References

  1. NICE Guideline NG71: Parkinson's disease in adults - Diagnosis and management
  2. Levodopa/Carbidopa/Entacapone Combination Therapy (StatPearls/NIH)

Frequently Asked Questions (FAQ)

Common questions about Claribid (FAQ)

Q: Is Claribid an antibiotic in the penicillin family?

According to official classification, Claribid is a macrolide antibiotic, which belongs to a different family of drugs than penicillin. This classification suggests it may be considered for use where penicillin allergy is a factor for a healthcare provider to review.

Q: What are the common types of bacteria that Claribid is designed to eliminate?

Official regulatory documents state that Claribid is indicated for treating infections caused by susceptible organisms. These often include bacteria that cause infections in the respiratory tract, as well as those affecting the skin and soft tissue.

Q: Is the metallic or bitter taste a normal and expected side effect of taking Claribid?

An altered or abnormal taste sensation (dysgeusia) is one of the frequently reported side effects noted in official drug documents. Regulatory information describes this as a common reaction associated with the medicine.

Q: Is it common to develop a yeast infection (thrush) after completing a course of Claribid?

Official information indicates that using antibiotics like Claribid can disrupt the normal balance of microorganisms in the body. This disruption may create an opportunity for a secondary fungal infection, such as oral or vaginal thrush, to develop.

Q: What are general signs that Claribid might not be working to treat an infection?

While individual patient response can vary, official guidance for specific infections suggests that some patients may expect to see improvement after around seven days of therapy. A lack of improvement after this expected period is an observation for a patient's prescriber to consider.

Q: Is it normal to pass a piece of the tablet in the stool when taking the extended-release form?

Official product information describes that the outer shell of the extended-release (ER) tablet may sometimes be visible in the stool. This is a normal occurrence after the medicine inside the shell has been released and absorbed by the body.

Q: Is Claribid generally considered a 'strong' or potent antibiotic?

Claribid is classified by regulatory authorities as a semi-synthetic macrolide antibiotic and a crucial anti-infective agent. It addresses illnesses resulting from bacterial proliferation and is approved for managing a range of infections, including those that may be severe.

Q: Can consuming alcohol affect the safety or effectiveness of Claribid?

Patient information aligned with regulatory guidance generally indicates that consuming alcohol is not expected to affect the safety or effectiveness of Claribid. However, questions regarding alcohol consumption in the context of underlying health conditions are best addressed by a healthcare professional.

Q: Does Claribid interact with common herbal supplements or vitamins?

Official prescribing information strongly advises informing a healthcare provider about all medications, including herbal supplements and vitamins. This is because Claribid is known to interfere with how the body processes many different substances, which can lead to altered drug levels.

Q: Is there a known interaction between Claribid and hormonal birth control pills?

Regulatory-aligned drug interaction information notes that Claribid has the potential to increase or decrease the blood levels of hormonal birth control medicines that contain estrogen. The potential impact on contraceptive effectiveness is a factor for a patient’s healthcare provider to assess.

Q: Does Claribid interact with common medicines used to regulate blood pressure or heart rhythm?

Prescribing information notes that Claribid may interact with certain antiarrhythmics (medicines used for heart rhythm). Due to the risk of QT prolongation, caution is specifically required when Claribid is taken alongside any other medication that can affect heart rhythm.

Q: Are there special considerations or warnings for using Claribid in elderly patients (65 years and older)?

Official prescribing information advises caution for older adult patients (65 years and older). Regulatory documents note that this population may be more sensitive to certain side effects, including potential hearing loss and certain heart rhythm changes.

Q: What is Clostridium difficile associated diarrhea (CDAD) and how is it related to Claribid?

Clostridium difficile is a bacterium that can cause severe, persistent diarrhea and an inflammation of the colon known as colitis. This serious condition is a potential risk associated with the use of nearly all antibiotics, including Claribid, as the drug disrupts the gut flora.

Q: What are the differences in warnings for Claribid between the immediate-release and extended-release forms?

A key difference found in regulatory warnings relates to administration requirements. Extended-release tablets must be swallowed whole with food to ensure proper absorption and safety. Immediate-release tablets, by contrast, can be taken with or without food.

Q: Is it necessary to take the extended-release Claribid tablet with food, based on product information?

Yes, official prescribing instructions explicitly state that the extended-release tablets must be taken with food. This instruction is necessary to ensure the medicine is properly released and absorbed by the body as intended.

Q: Can Claribid treat infections caused by viruses, like the flu or common cold?

Claribid is classified as an antibiotic which is designed to specifically target and treat bacterial infections. Regulatory patient safety information states that Claribid is not effective against infections caused by viruses, such as the common cold or the flu.

Q: How long does Claribid generally stay in the body after the last dose is taken?

Regulatory pharmacokinetic data indicates that the active components of the medicine are generally eliminated from the body with a half-life of approximately 3 to 7 hours following the last dose. The exact time depends on the specific dosage taken and the patient's individual characteristics.

Q: Can stopping Claribid treatment too early lead to antibiotic resistance?

Regulatory information strongly emphasizes that the entire prescribed course must be completed. Stopping treatment early risks allowing bacteria that have not been killed to survive and continue to grow, which can contribute to the development of antibiotic-resistant bacteria.

Q: Why do some users report difficulty sleeping (insomnia) while taking Claribid?

Insomnia (difficulty sleeping) is formally listed as a common side effect in official drug information for Claribid. This is a known adverse reaction reported in clinical use.

Q: Are there any reported effects of Claribid on mood, anxiety, or mental state?

Official documents have reported serious adverse effects related to the nervous system and psychiatric state. These reports include instances of confusion, anxiety, hallucinations, and psychosis occurring in some patients.

Q: Can Claribid cause temporary hearing changes or dizziness?

Official drug information lists dizziness as a common side effect. Cases of temporary hearing loss (deafness) have also been reported, and this effect has been described in regulatory sources as generally reversible upon discontinuation of the medicine.

Q: Is tooth discoloration listed as a possible side effect of Claribid?

Tooth discoloration has been reported in official documents as a possible adverse reaction to Claribid. This discoloration is generally described in official reports as reversible after professional dental cleaning.

Q: Does Claribid interact with common over-the-counter pain relievers like paracetamol or ibuprofen?

Based on regulatory-aligned drug interaction information, no direct interaction has been identified between Claribid and common over-the-counter pain relievers such as ibuprofen or paracetamol (acetaminophen). However, patients should always notify their prescriber about all concurrent medications.

Q: Can the immediate-release Claribid tablets be crushed, cut, or split for easier swallowing?

Official administration instructions for Claribid tablets advise patients to swallow the tablets whole with a drink of water. Regulatory materials state that the tablets are not intended to be chewed or broken.

Q: Is Claribid considered habit-forming or addictive?

Claribid is an antibiotic and is therefore not classified or listed in regulatory schedules as a controlled substance. It is also not officially associated with being habit-forming or having abuse potential.

Q: Are there warnings about Claribid causing blood sugar changes in diabetic patients?

Official documents list hypoglycemia (low blood sugar) as a possible adverse effect of Claribid. The potential for blood sugar changes is an important consideration for patients who have conditions such as diabetes.

Q: Can Claribid cause a change in tongue color or appearance?

Tongue discoloration has been reported as a possible adverse reaction in official drug documents for Claribid.

Q: Is there a specific mechanism explaining the potential long-term increased risk of death in patients with coronary artery disease who have taken Claribid?

Official regulatory reviews, including those conducted by the FDA, have examined the potential long-term increased risk of death in patients with coronary heart disease who have taken Claribid. These reviews have concluded that no clear biological mechanism has been identified to explain this finding.

Q: What are the official signs of a serious or severe allergic reaction to Claribid?

Official patient safety information indicates that severe allergic reactions may be indicated by symptoms such as the sudden swelling of the face, lips, tongue, or throat. Other serious signs include difficulty breathing or swallowing.

Q: What is the guidance regarding Claribid use for women who are breastfeeding?

Regulatory information confirms that Claribid is excreted into human breast milk in small amounts. Official documents state that the safety of the medicine for use during breast-feeding has not been established.

Q: Has the use of Claribid been studied for safety and effectiveness in children younger than 6 months old?

Official prescribing information states that the safety and effectiveness of Claribid for general bacterial infections in infants younger than 6 months is not established.

How should Claribid be stored and disposed of?

Storage and Disposal of Claribid (Clarithromycin)

The medicine must be stored strictly according to official regulatory requirements to ensure stability.

Clarithromycin tablets require storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The tablets must be kept in the original, tightly closed container and protected from moisture and light.

Oral Suspension Storage and Stability

The reconstituted liquid suspension must be stored between 15 C and 30 C (59 F and 86 F). It is a mandatory requirement to not refrigerate or freeze the mixed liquid. Any unused portion of the suspension must be discarded after 14 days.

All forms of Claribid must be stored out of the reach and sight of children. Unused or expired medication must be disposed of in accordance with local requirements and should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Claribid found in:

A-Z Index: